Amazon Launches AI Research Tool to Speed Early-Stage Drug Discovery.

Amazon Web Services has launched Amazon Bio Discovery, which is an AI tool designed to accelerate early-stage drug discovery. An innovative platform, it allows scientists to generate and evaluate potential drug molecules without the need for coding.  

This tool provides access to a library of specialized biological foundation models and an AI agent that assists users in selecting models, setting parameters, and interpreting results. It aims to augment, not replace, scientists and contract research organizations, significantly reducing the time to create drug candidates from months to weeks.  

According to Towards Healthcare, the ​​pharma cloud services market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 12.47 billion in 2026 to approximately USD 43.18 billion by 2035, representing a compound annual growth rate (CAGR) of 14.8% from 2026 to 2035. Growth is driven by the increasing adoption of decentralized and virtual clinical trials, which transform how trials are conducted by enabling remote patient participation through telemedicine, wearable devices, ePROs, and home-based data collection, also with the rise of AI-assisted drug discovery and precision medicine, which relies heavily on cloud computing capabilities. 

About Amazon Web Services  

Amazon Web Services has introduced Amazon Bio Discovery, an AI application designed to facilitate early-stage drug discovery by allowing researchers to perform complex tasks without coding. This tool provides access to specialized biological models and integrates lab partners for testing, reducing drug development time. Amazon says Bio Discovery is intended to assist, not replace, scientists. 

AWS said Bayer, the Broad Institute, and Voyager Therapeutics are among early adopters, and 19 of the top 20 global pharmaceutical companies already use its cloud services. 

Bayer and Voyager Therapeutics are among early adopters of the tool, which has also been utilized in a collaboration with Memorial Sloan Kettering Cancer Center. 

Vice president of healthcare AI and life sciences at AWS, Rajiv Chopra, stated that the rapid rise of drug-discovery models has turned computational biologists who ​can translate lab goals into machine-learning pipelines into a bottleneck. 

The whole platform has its own AI that can help guide appropriate model selection or choose top candidates. Memorial Sloan Kettering Cancer Center already reported good results by using Amazon Bio Discovery to design 300K novel antibodies for pediatric cancer care and filter down to the top 100K before validating in a wet lab within weeks, vs. up to a year traditionally. 

A recent report by Towards Healthcare highlights that the ​​pharma cloud services market is witnessing growth due to the increasing demand for cloud-based solutions in drug development, regulatory compliance, and data management. Fueled the rise of hybrid cloud models, ensuring data sovereignty and compliance with global regulations.